Bionor Q1 2016 Interim Financial Report
(Thomson Reuters ONE) -
BIONOR PHARMA ASA
INTERIM FINANCIAL REPORT
1 JANUARY - 31 MARCH 2016
UNAUDITED
11 MAY 2016
HIGHLIGHTS Q1 2016
In the first quarter of 2016, Bionor continued its preparation of the BIOSKILL
trial and other clinical activities. Additional clinical trial applications for
BIOSKILL were forwarded to competent authorities, and the company also reported
further data from the REDUC Part B trial. The company's working capital was
strengthened with the support from existing and new shareholders in a NOK 45
million private placement and a subsequent NOK 16 million repair offering.
* REDUC Part B results, primarily related to latent reservoir size, were given
as an oral presentation at the prestigious Conference on Retroviruses and
Opportunistic Infections (CROI), in Boston, MA (USA)
* Bionor announced that the third and final assay for measuring latent HIV
reservoir size, the primary endpoint in the REDUC Part B trial, supports
that the combination of Vacc-4x and the latency reversing agent romidepsin
(Istodax®, Celgene) leads to a reduction in latent viral reservoir
* Clinical trial applications for the BIOSKILL clinical trial were submitted
to authorities in France and Australia, and approval was obtained in Denmark
and the United Kingdom. In addition, a request for a pre-IND meeting with
the U.S. Food and Drug Administration (FDA) was submitted
* Bionor was granted up to NOK 9.2 million from Research Council of Norway to
further advance Vacc-4x in a combination treatment regimen
* The company's shareholders approved the completion of a private placement
raising NOK 45 million in gross proceeds, which is expected to fund the
company through the first half of 2016, and a subsequent repair offering for
existing shareholders raising gross proceeds of NOK 16 million
* A new Chairman and two new board members were elected at an extraordinary
general meeting on 11 March 2016
* Net cash flow in Q1 2016 was NOK -31.2 million (Q1 2015: NOK -17.8 million)
* Cash and cash equivalents at 31 March 2016 was NOK 41.8 million (31 March
2015: NOK 75.3 million).
Events after the balance sheet date
* At the company's annual general meeting on 22 April 2016, a number of
resolutions were rejected by the shareholders. Mr. Steen Krøyer was elected
as new board member, replacing Thomas Hofstaetter. An extraordinary general
meeting will be convened shortly to handle the rejected proposals
* On 26 April 2016, the company announced that Dr. David Horn Solomon and
Bionor's Board of Directors had agreed that Dr. David Horn Solomon on the
same day would leave his position as Chief Executive Officer of Bionor
Pharma ASA, owing to a shareholder led change in company strategy. The Board
of Directors will initiate a search process for a new CEO. Until such search
is concluded, the Board has appointed MSc Pharm Unni Hjelmaas as acting CEO
* Three board members, Benedicte Fossum, Kirsten Drejer and Jerome B. Zeldis
resigned from the Board on 28 April 2016.
Financial guidance for 2016
For the full year 2016, Bionor maintains its financial guidance of a Core cost
base in the range of NOK 58-66 million. The Core cost base is defined as
Employee Benefit Expenses plus Other operating expenses.
Per S. Thoresen, Chairman of the Board of Directors, commented:
"The new Board maintains its focus on HIV immunotherapy and the overall strategy
to advance Vacc-4x in combination with other medicines in order to contribute to
a possible functional HIV cure. With 36 million people world-wide living with
HIV, it is of paramount importance that treatment options for HIV-positive
individuals are improved. We have a strong asset in Vacc-4x, and as Board and
company, we look forward to advancing our functional HIV cure strategy to the
future benefit of HIV-positive individuals and their caregivers as well as to
our shareholders. The timing and details in the clinical development program as
well as the core cost base are under consideration in light of the company's
cash position and market capitalization. Any possible changes will be disclosed
in due course in a stock exchange announcement."
The full Interim Financial Report for Q1 2016 is attached.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Further information
Per S. Thoresen, Chairman of the Board of Directors, +47 906 14 620
Jens Krøis, CFO, +45 2080 1668, jk(at)bionorpharma.com
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 2030 3903,
jfr(at)bionorpharma.com
About Bionor
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its
proprietary therapeutic vaccine Vacc-4x in combination with other medicines
toward a functional HIV cure. The company believes it has first mover potential
based on clinical results to date and early adoption of now recognized clinical
strategy. In December 2015, Bionor announced that the HIV 'Shock & Kill' trial
REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by
reducing latent HIV reservoir and further demonstrated control of viral load.
Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside
potential from partnering or licensing remains with the company. Bionor is based
in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA.
Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is
available at www.bionorpharma.com.
Bionor Q1 2016 Interim Financial Report:
http://hugin.info/131219/R/2011505/744738.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bionor Pharma ASA via GlobeNewswire
[HUG#2011505]
Unternehmensinformation / Kurzprofil:
Datum: 11.05.2016 - 07:59 Uhr
Sprache: Deutsch
News-ID 470182
Anzahl Zeichen: 6792
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 214 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bionor Q1 2016 Interim Financial Report"
steht unter der journalistisch-redaktionellen Verantwortung von
Bionor Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
